共 71 条
[61]
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
[J].
ANNALS OF THE RHEUMATIC DISEASES,
2014, 73 (06)
:990-999
[62]
Efficacy of infliximab in resistant psoriatic arthritis
[J].
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH,
2003, 49 (04)
:541-545
[63]
Sarzi-Puttini P, 2001, CLIN EXP RHEUMATOL, V19, pS17
[65]
Schett G, 2013, ARTHRITIS RHEUM-US, V65, pS143
[67]
Soriano ER, 2006, J RHEUMATOL, V33, P1422
[69]
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial
[J].
BMJ-BRITISH MEDICAL JOURNAL,
2010, 340
:300
[70]
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment - Results from the induction and maintenance psoriatic arthritis clinical trial 2
[J].
ARTHRITIS AND RHEUMATISM,
2007, 56 (08)
:2698-2707